Abstract
Peripheral T- and NK-cell lymphomas (PT/NKCLs) are relatively rare, and few studies have validated the International Prognostic Index (IPI) for PT/NKCLs in prospective clinical trials. Histopathological specimens from 136 patients, enrolled in six prospective multicenter trials of doxorubicin-containing regimens, with PT/NKCLs were reviewed by six hematopathologists following the WHO classification. This combined analysis demonstrated that the IPI was not predictive of prognosis for patients with PT/NKCLs as previously shown by GELA. In a univariate analysis, low total serum protein (TP) and albumin levels, gastrointestinal tract involvement, and histologic subtype (extranodal NK/T-cell lymphoma, nasal type, and peripheral T-cell lymphoma, unspecified) were significantly associated with reduced survival. In a multivariate analysis, TP (p = 0.004) and histologic subtype (p = 0.024) remained significant. We discuss the need to establish the importance and meaning of TP and to develop new strategies for patients with PT/NKCLs allowing for TP, especially with worse histologic subtypes.
Acknowledgements
We thank Masahiro Kikuchi (Fukuoka University), Yoshihiro Matsuno (Hokkaido University), and Tadashi Yoshino (Okayama University) for conducting the pathology review and serving as members of an expert panel, and Yoshihiro Matsuno for his assistance in writing the histopathological and immunohistochemical by central review analyses portion of the manuscript.
Declaration of interest: This study was supported by Grants-in-Aid No. 2S-1, 5S-1, 8S-1, 11S-1, 11S-4, 14S-1, 14S-4, 17S-1, and 17S-5 for Cancer Research from the Ministry of Health, Labor and Welfare of Japan.